PharmaCyte Biotech, Inc.
PMCB · XNASCIK 1157075fmd_0NBYESKYAH8YVF5KHFTX0J9KBCManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: May 01, 2010 to Jul 31, 2026, 65 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Research and development | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 4 | 7 | 4 | 4 | 4 | 4 | 6 | 9 | 4 | 7 |
| Compensation and benefits | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | – | – |
| Operating income | (4) | (7) | (4) | (4) | (4) | (4) | (6) | (9) | (4) | (7) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | 0 | 0 | (0) | 0 | 0 | 2 | 9 | 35 | (13) |
| Income before taxes | – | – | – | – | – | – | – | – | 31 | (19) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | 31 | (19) |
| Net income | (4) | (7) | (4) | (4) | (4) | (4) | (4) | 0 | 31 | (19) |
| Net income to common shareholders | – | – | – | – | – | – | (4) | (17) | 23 | (23) |